T-cell Brazil project started in April 2017 an ambispective study focusing to collecting epidemiological and clinical data from the most frequent subtypes of PTCL. Our goals are to obtain the frequency of subtypes by the five Brazilian macro regions; to investigate the clinical and biology characteristic; to create a routine pathological revision and to evaluate the OS, EFS in 5 years of follow-up.

Thirteen nine centers had approved by their Ethical Committee and using REDcap Platform by Vanderbilt are registering their cases. Descriptive and bivariate analyses, then it was applied Kaplan-Meier method and log-rank test to obtain survival estimates, using IBM-SPSS v.24

The median age was 55 years (19-95); 56% male; Almost 72% had advanced stages, 28% ECOG ≥ 2; the distribution of main subtypes was: 31% PTCL-NOS; 18% ALCL, ALK-; 16% ATL; 13% ENKTL nasal and nasal type; 11% AITL; 7% ALCL, ALK+; 6% others (Table 1). 50% of patients were alive and the 24-month PFS and OS was 36% and 50%, respectively. OS by main subtypes was 48% PTCL-NOS; 61% ALCL, ALK-; 33% ATL; 46% ENKTL nasal/nasal type; 48% AITL; 80% ALCL, ALK+.

This is the first experience cover all over the country, focusing also an educational and of interchanging experience network among the multidisciplinary health team in Brazil. The target of 500 was exceeded; however, the registry will go on until December as planned. All cases have been reviewed both in the registry and by pathologist Committee, and we esteem some cases will be excluded for different reasons and anyway it will help for future analyses if the number of registers is higher.